swissmedic

Date: 19 November 2024
Swissmedic, Swiss Agency for Therapeutic Products

Swiss Public Assessment Report
Extension of therapeutic indication

Enhertu

International non-proprietary name: trastuzumab deruxtecan

Pharmaceutical form: powder for concentrate for solution for infusion

Dosage strength(s): 100 mg

Route(s) of administration: intravenous use

Marketing authorisation holder: Daiichi Sankyo (Schweiz) AG

Marketing authorisation no.: 67967

Decision and decision date: extension of therapeutic indication as a temporary authorisation in accordance with Art. 9a TPA approved on 8 May 2024

Note:

This assessment report is as adopted by Swissmedic with all information of a commercially confidential nature deleted.

SwissPARs are final documents that provide information on submissions at a particular point in time. They are not updated after publication.

Table of contents

1 Terms, Definitions, Abbreviations

1L	First-line
2L	Second-line
ADA	Anti-drug antibody
ADME	Absorption, distribution, metabolism, elimination
AE	Adverse event
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
API	Active pharmaceutical ingredient
ATC	Anatomical Therapeutic Chemical Classification System
AUC	Area under the plasma concentration-time curve
$AUC_{0\text{-}24h}$	Area under the plasma concentration-time curve for the 24-hour dosing interval
CI	Confidence interval
C_{max}	Maximum observed plasma/serum concentration of drug
cORR	Confirmed objective response rate
CYP	Cytochrome P450
DCO	Data cut-off
DDI	Drug-drug interaction
DOR	Duration of response
ECOG	Eastern Cooperative Oncology Group
EMA	European Medicines Agency
ERA	Environmental risk assessment
FDA	Food and Drug Administration (USA)
GC	Gastric cancer
GEJ	Gastroesophageal junction
GEJC	Gastroesophageal junction adenocarcinoma
GLP	Good Laboratory Practice
HER2	Human epidermal growth factor receptor 2
HPLC	High-performance liquid chromatography
IC/EC_{50}	Half-maximal inhibitory/effective concentration
ICH	International Council for Harmonisation
ICR	Independent central review
Ig	Immunoglobulin
INN	International non-proprietary name
ITT	Intention-to-treat
LoQ	List of Questions
MAH	Marketing Authorisation Holder
Max	Maximum
Min	Minimum
MRHD	Maximum recommended human dose
MTD	Maximum tolerated dose
N/A	Not applicable
NCCN	National Comprehensive Cancer Network
NE	Not estimable
NO(A)EL	No observed (adverse) effect level
ORR	Objective response rate
OS	Overall survival
PBPK	Physiology-based pharmacokinetics
PD	Pharmacodynamics
PFS	Progression-free survival
PIP	Paediatric Investigation Plan (EMA)
PK	Pharmacokinetics
PopPK	Population pharmacokinetics

PSP	Pediatric study plan (US FDA)
Q3W	Every 3 weeks
RMP	Risk management plan
SAE	Serious adverse event
SAT	Single-arm trial
SwissPAR	Swiss Public Assessment Report
TEAE	Treatment-emergent adverse event
TPA	Federal Act of 15 December 2000 on Medicinal Products and Medical Devices (SR 812.21)
TPO	Ordinance of 21 September 2018 on Therapeutic Products (SR 812.212.21)
T-DXd	Trastuzumab deruxtecan

2 Background information on the procedure

2.1 Applicant's request(s)

Extension(s) of the therapeutic indication(s)
The applicant requested the addition of a new therapeutic indication or modification of an approved one in accordance with Article 23 TPO.

Temporary authorisation for human medicinal products
The applicant requested a temporary authorisation in accordance with Article 9a TPA.

2.2 Indication and dosage

2.2.1 Requested indication

Enhertu as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

2.2.2 Approved indication

Enhertu as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have disease progression on or after a first-line regimen with trastuzumab and chemotherapy.

2.2.3 Requested dosage

Summary of the requested standard dosage:

6.4 mg/kg body weight as an intravenous infusion once every 3 weeks (Q3W).

2.2.4 Approved dosage

(see appendix)

2.3 Regulatory history (milestones)

Application	31 March 2023
Formal control completed	13 April 2023
List of Questions (LoQ)	3 August 2023
Response to LoQ	9 November 2023
Preliminary decision	16 January 2024
Response to preliminary decision	15 March 2024
Final decision	8 May 2024
Decision	approval (temporary authorisation in accordance with Art. 9a TPA)

3 Medical context

Locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) is an incurable disease. Overexpression of the human epidermal growth factor receptor 2 (HER2) protein is reported in approximately 20% of patients with GC[1] and additional targeted therapy is available for such patients. Most patients in Western countries present with inoperable disease requiring palliative treatment. Five-year survival for advanced or metastatic gastric cancer is around 6%[2], with median overall survival ranging from 6 to 14 months in the first-line treatment setting[3]. Once HER2-positive GC/GEJC patients have progressed after a first-line regimen that includes anti-HER2 therapy, the disease outcomes are poor. An antiangiogenic monoclonal antibody in combination with a taxane is approved for the second-line treatment of GC/GEJC, regardless of HER2 expression. In a more pre-treated setting (third-line or later) regardless of biomarker, authorised options include an immune checkpoint inhibitor or combination treatment with a nucleoside analogue and a thymidine phosphorylase inhibitor. Other clinically acceptable, but not authorised, treatment options for pre-treated all-comer GC/GEJC patients include a single-agent taxane, a topoisomerase inhibitor, or fluoropyrimidine-based combination chemotherapy. Currently, there is no approved targeted anti-HER2 therapy in Switzerland for the treatment of advanced HER2-positive GC/GEJC in second-line or later settings (i.e. population with a poor prognosis and limited treatment options), resulting in an unmet need.

[1] Faria Abrahao-Machado L et Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016 May 21; 22(19): 4619–4625.
[2] Stomach Cancer: Statistics, www.cancer.net, approved by the Cancer.Net Editorial Board, 08/2023
[3] Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97

4 Nonclinical aspects

The applicant did not submit any new nonclinical studies to support the requested extension of the indication, which is acceptable. Based on the ERA, the extension of the indication will not be associated with an increased risk for the environment. From the nonclinical point of view, there are no objections to the approval of the proposed new indication.

5 Clinical aspects

5.1 Clinical pharmacology

The available assessment report from the EMA and respective product information documents from the EMA and FDA were used as a basis for the clinical pharmacology evaluation.

5.2 Dose finding and dose recommendation

The requested dose of trastuzumab deruxtecan (T-DXd) is 6.4 mg/kg every 3 weeks (Q3W) for the second-line (and later) treatment of HER2 positive GC/GEJC, which is higher than the authorised dose for breast cancer indications (i.e. 5.4 mg/kg Q3W). The applicant presented data from study DS8201-A-J101 to support the request for a T-DXd monotherapy dose of 6.4 mg/kg Q3W. This Phase 1 study of T-DXd in patients with advanced solid malignant tumours included a dose escalation part evaluating a dose range of 0.8 mg/kg to 8.0 mg/kg Q3W to identify the maximum tolerated dose and the recommended Phase 2 dose. Doses up to 8.0 mg/kg were tolerable and no drug-limiting toxicity was reported during the first cycle of treatment. The maximum tolerated dose was not reached. Doses of 5.4 mg/kg and 6.4 mg/kg administered every 3 weeks were selected for the dose expansion part of the study.

One of the cohorts of study DS8201-A-J101 included patients with trastuzumab-exposed advanced HER2-overexpressing GC/GEJC. In this cohort, patients were treated with either a 5.4 mg/kg or a 6.4 mg/kg dose of T-DXd. Descriptive results demonstrated higher confirmed objective response rates (cORR) as well as a longer duration of response (DOR) for the 6.4 mg/kg dose compared with 5.4 mg/kg. However, the higher dose was also associated with increased toxicity. Pooled analyses of all study DS8201-A-J101 patients treated with the 6.4 mg/kg compared with the 5.4 mg/kg dose showed an increased frequency of grade ≥3 treatment-emergent adverse events (TEAEs), TEAEs with outcome of death, serious adverse events, TEAEs leading to drug discontinuation, and TEAEs leading to dose reduction. The increase in grade ≥3 TEAEs for the 6.4 mg/kg dose compared with 5.4 mg/kg was mostly driven by blood and lymphatic disorders such as neutrophil count decreased and platelet count decreased, and the difference in TEAEs leading to drug discontinuation was driven by pneumonitis and interstitial lung disease.

In summary, the requested T-DXd dose of 6.4 mg/kg Q3W is higher than the previously authorised dose of 5.4 mg/kg Q3W and is associated with increased toxicity. However, no new safety signals were identified and the adverse reactions are adequately described in the Information for healthcare professionals. The requested dose is overall acceptable. However, it cannot be ruled out that a different dose strength or treatment interval might have provided a more favourable benefit-risk profile.

5.3 Efficacy

Results from two clinical trials were provided: study DESTINY-Gastric02 (DS8201-A-U205), which is the pivotal study, and study DESTINY-Gastric01 (DS8201-A-J202), which is a supportive study for the requested indication.

The DESTINY-Gastric02 study was a Phase 2, multicentre, single-arm, open-label trial to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd, 6.4 mg/kg as an intravenous infusion Q3W) in 79 subjects with unresectable or metastatic HER2-positive GC/GEJC who had progressed during or after a trastuzumab-containing regimen (second-line and later setting). The study was conducted in the US and Europe.

The primary efficacy endpoint was the confirmed ORR by independent central review (ICR). At the data cut-off (DCO) in November 2021, the confirmed ORR was 41.8% (CI95% 30.8%, 53.4%) and the median confirmed DOR was 8.1 months (CI95% 5.9, NE).

The DESTINY-Gastric01 study was a Phase 2, multicentre, open-label, 2:1 randomised trial to evaluate efficacy and safety in subjects with advanced HER2-positive GC/GEJC who had progressed on 2 or more prior regimens including a fluoropyrimidine agent and a platinum agent in addition to prior trastuzumab. The study was conducted in Japan and South Korea. The patient population included in the study is not representative of the Swiss population because only Asian patients, who have a better prognosis[4], were included. In addition, included patients previously received three or more lines of therapy. Therefore, the results of this study were only accepted as supportive data. In the Primary Cohort (N=188) of this study, subjects were randomised to receive either T-DXd monotherapy at the proposed dose (6.4 mg/kg Q3W, n=126) or treatment of physician's choice (irinotecan or paclitaxel, n=62). The primary efficacy endpoint was the unconfirmed ORR by ICR, and overall survival (OS) was a statistically controlled secondary endpoint. This study met its primary endpoint of improved unconfirmed ORR in the experimental arm. According to the DCO from June 2020, the updated confirmed ORR by ICR was 39.7% in the experimental arm compared to 11.3% in the control arm. The study also demonstrated a statistically significant difference in OS.

Please refer to the Information for healthcare professionals for further details.

5.4 Safety

The most frequently reported (≥25%) treatment-emergent adverse events of any grade in the T-DXd 6.4 mg/kg HER2+ gastric cancer pool (N=229) included nausea, decreased appetite, anaemia, neutrophil count decreased, vomiting, diarrhoea, platelet count decreased, white blood cell count decreased, fatigue, and constipation. Another noteworthy known toxicity for T-DXd is interstitial lung disease. No new safety signals were identified and the adverse reactions are adequately described and addressed in the Information for healthcare professionals. Further safety data are awaited from the ongoing confirmatory Phase 3 study DESTINY-Gastric04.

5.5 Final clinical benefit-risk assessment

Locally advanced or metastatic HER2-positive GC/GEJC is an incurable disease. Despite the available treatment options, there is a need to further improve the treatment outcomes in these patients. Once HER2-positive GC/GEJC patients have progressed after a first-line regimen that includes trastuzumab, the prognosis is poor.

The reported response rates and results of time-to-event analyses from studies DESTINY-Gastric02 and DESTINY-Gastric01 exceed the published efficacy results of current standard treatments in this setting[5,6] and the results were accepted for a temporary authorisation. The overall safety is manageable, and the safety risks are described in the Information for healthcare professionals. Given the limitations associated with the uncontrolled single-arm design of the pivotal study confirmatory results are necessary. To confirm a clinical benefit as a condition of temporary authorisation, the applicant committed to submit data of the ongoing study DESTINY-Gastric04 (a Phase 3 randomised controlled trial of T-DXd versus ramucirumab combined with paclitaxel in second-line patients that includes a Western population) prior to the expiration of the temporary authorisation.

[4] Strong VE et al. Comparison of Gastric Cancer Survival Between the United States and Korea Using an Internationally Validated Nomogram. Annals of Surgery. 2010 Oct;252(4):640-64
[5] Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35
[6] Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov; 19(11):1437-1448

6 Risk management plan summary

The RMP summaries contain information on the medicinal products' safety profiles and explain the measures that are taken to further investigate and monitor the risks, as well as to prevent or minimise them.
The RMP summaries are published separately on the Swissmedic website. It is the responsibility of the marketing authorisation holder to ensure that the content of the published RMP summaries is accurate and correct. As the RMPs are international documents, their summaries might differ from the content in the Information for healthcare professionals / product information approved and published in Switzerland, e.g. by mentioning risks that occur in populations or indications not included in the Swiss authorisations.

7 Appendix

Approved Information for healthcare professionals

Please be aware that the following version of the Information for healthcare professionals for Enhertu was approved with the submission described in the SwissPAR. This Information for healthcare professionals may have been updated since the SwissPAR was published.

Please note that the valid and relevant reference document for the effective and safe use of medicinal products in Switzerland is the Information for healthcare professionals currently authorised by Swissmedic (see www.swissmedicinfo.ch).

Note:
The following Information for healthcare professionals has been translated by the MAH. It is the responsibility of the authorisation holder to ensure the translation is correct. The only binding and legally valid text is the Information for healthcare professionals approved in one of the official Swiss languages.

Interstitial lung disease (ILD) and/or pneumonitis, including fatal cases, have been reported with Enhertu. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue Enhertu in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms. Patients with moderate renal impairment are at increased risk of developing ILD including fatal cases (see sections “Warnings and precautions” and “Undesirable Effects”).

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected new or serious adverse reactions. See the "Undesirable effects" section for advice on the reporting of adverse reactions.
Enhertu has indications that have been granted temporary authorisation, see the “Indications/Uses” section.

ENHERTU® 100 mg powder for concentrate for solution for infusion

Composition

Active substances

Trastuzumabum deruxtecanum is composed of an antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) conjugated via a linker to the topoisomerase I inhibitor DXd.

Excipients

L-histidinum, L-histidini hydrochloridum monohydricum, saccharum, polysorbatum 80.

Pharmaceutical form and active substance quantity per unit

Powder for concentrate for solution for infusion.
White to yellowish white lyophilised powder.
One vial of lyophilised powder for concentrate for solution for infusion contains 100 mg of trastuzumab deruxtecan.

Indications/Uses

Indications with standard authorisation

Breast cancer

HER2-positive breast cancer

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens, including trastuzumab and a taxane, and had a progression either in the metastatic setting or within 6 months after finalization of an adjuvant or neoadjuvant therapy (see section "Properties/Effects").

HER2-low breast cancer

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy (see section "Properties/Effects").

Indication(s) with temporary authorisation

Gastric cancer

Enhertu as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have disease progression on or after a first-line regimen with trastuzumab and chemotherapy.

This indication has been granted temporary authorisation as the clinical data were incomplete at the time the application was assessed (Art. 9a Therapeutic Products Act). The temporary authorisation is contingent on the timely fulfilment of conditions. After they have been met, the temporary authorisation can be converted into a standard authorisation.

Dosage/Administration

Enhertu should be prescribed by a physician and administered under the supervision of a healthcare professional experienced in the use of anticancer medicinal products. In order to prevent medicinal product errors, it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Enhertu (trastuzumab deruxtecan) and not trastuzumab or trastuzumab emtansine.
Do not substitute Enhertu for or with trastuzumab or trastuzumab emtansine.

Patient selection for HER2-low metastatic breast cancer

Select patients for treatment of unresectable or metastatic HER2-low breast cancer based on IHC 1+ or IHC 2+/ISH- tumor status, as assessed by a validated test (see section “Properties/Effects”).

Patient selection for gastric cancer

Patients treated with trastuzumab deruxtecan for gastric or gastroesophageal junction cancer should have documented HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry (IHC) or a ratio of ≥ 2 by *in situ* hybridization (ISH) or by fluorescence *in situ* hybridization (FISH), assessed by a validated test. Whenever possible a new tumor specimen is to be obtained to reassess the HER2 status before treatment with Enhertu.

Premedication

Enhertu is moderately emetogenic (see section “Undesirable Effects”), which includes delayed nausea and/or vomiting. Prior to each dose of Enhertu, patients can take antiemetic drugs in accordance with consensus-based and/or local guidelines as per tolerance for prophylaxis or management.

Posology

The initial dose should be administered as a 90-minute intravenous infusion. If the prior infusion was well tolerated, subsequent doses of Enhertu may be administered as 30-minute infusions.
The infusion rate of Enhertu should be slowed or interrupted if the patient develops infusion-related symptoms. Enhertu should be permanently discontinued in case of severe infusion reactions.
To ensure traceability of biotechnological medicinal products, it is recommended that the trade name and batch number should be documented for each treatment.

Breast cancer

The recommended dose of Enhertu is 5.4 mg/kg given as an intravenous infusion once every three weeks (21-day cycle) until disease progression or unacceptable toxicity.

Gastric cancer

The recommended dose of Enhertu is 6.4 mg/kg given as an intravenous infusion once every three weeks (21-day cycle) until disease progression or unacceptable toxicity.

Dose modifications

Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of Enhertu per guidelines provided in Tables 1 and 2.
Enhertu dose should not be re-escalated after a dose reduction is made.

Table 1: Dose reduction schedule

Dose reduction schedule	Breast cancer	Gastric cancer
Starting dose	5.4 mg/kg	6.4 mg/kg
First dose reduction	4.4 mg/kg	5.4 mg/kg
Second dose reduction	3.2 mg/kg	4.4 mg/kg
Requirement for further dose reduction	Discontinue treatment.	Discontinue treatment

Table 2: Dose modifications for adverse reactions

Adverse reaction	Severity	Treatment modification
Interstitial lung disease (ILD)/pneumonitis	Asymptomatic ILD/pneumonitis (Grade 1)	Interrupt Enhertu until resolved to Grade 0, then: • if resolved in 28 days or less from date of onset, maintain dose. • if resolved in greater than 28 days from date of onset, reduce dose one level (see Table 1). • consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (see section “Warnings and precautions”).
	Symptomatic ILD/pneumonitis (Grade 2 or greater)	• Permanently discontinue Enhertu. • Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected (see section “Warnings and precautions”).
Neutropenia	Grade 3 (less than 1.0-0.5 × 10^9/L)	• Interrupt Enhertu until subsided to Grade 2 or less, then maintain dose.
	Grade 4 (less than 0.5 × 10^9/L)	• Interrupt Enhertu until subsided to Grade 2 or less. • Reduce dose by one level (see Table 1).

Adverse reaction	Severity		Treatment modification
Febrile neutropenia	Absolute neutrophil count of less than 1.0 × 10^9/L and temperature greater than 38.3°C or a sustained temperature of 38°C or greater for more than one hour.		• Interrupt Enhertu until resolved. • Reduce dose by one level (see Table 1).
Left ventricular ejection fraction (LVEF) decreased	LVEF greater than 45% and absolute decrease from baseline is 10% to 20%		• Continue treatment with Enhertu.
	LVEF 40% to 45%	And absolute decrease from baseline is less than 10%	• Continue treatment with Enhertu. • Repeat LVEF assessment within 3 weeks.
		And absolute decrease from baseline is 10% to 20%	• Interrupt Enhertu. • Repeat LVEF assessment within 3 weeks. • If LVEF has not recovered to within 10% from baseline, permanently discontinue Enhertu. • If LVEF recovers to within 10% from baseline, resume treatment with Enhertu at the same dose.
	LVEF less than 40% or absolute decrease from baseline is greater than 20%		• Interrupt Enhertu. • Repeat LVEF assessment within 3 weeks. • If LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed, permanently discontinue Enhertu.
	Symptomatic congestive heart failure (CHF)		• Permanently discontinue Enhertu.

Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0).

Delayed or missed dose

If a planned dose is delayed or missed, it should be administered as soon as possible without waiting until the next planned cycle. The schedule of administration should be adjusted to maintain a 3-week interval between doses. The infusion should be administered at the dose and rate the patient tolerated in the most recent infusion.

Special populations

Elderly patients

No dose adjustment of Enhertu is required in patients aged 65 years or older. Limited data are available in patients ≥75 years of age.

Patients with renal impairment

No dose adjustment is required in patients with mild (creatinine clearance [CLcr] ≥60 and <90 mL/min) or moderate (CLcr ≥30 and <60 mL/min) renal impairment (see section “Pharmacokinetics”). Limited data are available in patients with severe renal impairment. A higher incidence of ILD/pneumonitis leading to an increase in discontinuation of therapy has been observed in patients with moderate renal impairment. Patients with moderate or severe renal impairment should be monitored carefully (see section “Warnings and precautions”).

Patients with hepatic impairment

No dose adjustment is required in patients with mild (total bilirubin ≤ upper limit of normal [ULN] and any aspartate transaminase [AST] >ULN or total bilirubin >1 to 1.5 times ULN and any AST) hepatic impairment. There are limited data to make a recommendation on dose adjustment in patients with moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment (see section “Pharmacokinetics”). No data are available in patients with severe (total bilirubin >3 to 10 times ULN and any AST) hepatic impairment.

Children and adolescents

The safety and efficacy in children and adolescents below 18 years of age have not been established as there is no relevant use in the paediatric population.

Mode of administration

Enhertu is for intravenous use. It must be reconstituted and diluted by a healthcare professional and administered as an intravenous infusion. Enhertu must not be administered as an intravenous push or bolus.
For instructions on reconstitution and dilution of the medicinal product before administration, see section “Other information”, “Instructions and special precautions for handling and disposal”.

Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section “Composition”.

Warnings and precautions

Interstitial lung disease/pneumonitis

Cases of interstitial lung disease (ILD), and/or pneumonitis, have been reported with Enhertu (see section “Undesirable effects”). Fatal outcomes have been observed.
Patients with a history of ILD/pneumonitis requiring steroid treatment or present or suspected ILD/pneumonitis at the time of screening and patients with clinically severe pulmonary impairment were not included in clinical studies with Enhertu.
Patients should be advised to immediately report cough, dyspnoea, fever, and/or any new or worsening respiratory symptoms. Patients should be monitored for signs and symptoms of ILD/pneumonitis. Evidence of ILD/pneumonitis should be promptly investigated. Patients with suspected ILD/pneumonitis should be evaluated by further evaluation of the lung using imaging techniques. Consultation with a pulmonologist should be considered. For asymptomatic (Grade 1) ILD/pneumonitis, consider corticosteroid treatment (e.g. ≥0.5 mg/kg/day prednisolone or equivalent). Enhertu should be withheld until recovery to Grade 0 and may be resumed according to instructions in Table 2 (see section “Dosage/Administration”). For symptomatic ILD/pneumonitis (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g. ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks. Enhertu should be permanently discontinued in patients who are diagnosed with symptomatic (Grade 2 or greater) ILD/pneumonitis (see section “Dosage/Administration”). Patients with a history of ILD/pneumonitis or moderate or severe renal impairment may be at increased risk of developing ILD/pneumonitis and, therefore, should be monitored carefully (see section “Properties/Effects” and “Dosage/Administration”).

Neutropenia

Cases of neutropenia, including febrile neutropenia, were reported in clinical studies of Enhertu. Complete blood counts should be monitored prior to initiation of Enhertu and prior to each dose, and as clinically indicated. Based on the severity of neutropenia, Enhertu may require dose interruption or reduction (see section “Dosage/Administration”).

Left ventricular ejection fraction decrease

Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies. LVEF should be assessed prior to initiation of Enhertu and at regular intervals during treatment as clinically indicated. LVEF decrease should be managed through treatment interruption. Enhertu should be permanently discontinued if LVEF of less than 40% or absolute decrease from baseline of greater

than 20% is confirmed. Treatment with Enhertu has not been studied in patients with LVEF less than 50% prior to initiation of treatment. Enhertu should be permanently discontinued in patients with symptomatic congestive heart failure (CHF) (see section “Dosage/Administration”).

Embryo-foetal toxicity

Enhertu can cause foetal harm when administered to a pregnant woman. In postmarketing reports, use of trastuzumab, a HER2 receptor antagonist, during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Based on findings in animals and its mechanism of action, the topoisomerase I inhibitor component of Enhertu, DXd, can also cause embryo-foetal harm when administered to a pregnant woman (see section “Pregnancy, lactation”).
The pregnancy status of females of reproductive potential should be verified prior to the initiation of Enhertu. The patient should be informed of the potential risks to the foetus. Females of reproductive potential should be advised to use effective contraception during treatment and for at least 7 months following the last dose of Enhertu. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with Enhertu and for at least 4 months after the last dose of Enhertu (see section “Pregnancy, lactation”).

Patients with moderate or severe hepatic impairment

There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. As metabolism and biliary excretion are the primary routes of elimination of the topoisomerase I inhibitor, DXd, Enhertu should be administered with caution in patients with moderate and severe hepatic impairment (see section “Dosage/Administration” and “Pharmacokinetics”).

Interactions

Effects of other medicinal products on the pharmacokinetics of Enhertu

In vitro, DXd was a substrate of P-gp, OATP1B1, OATP1B3, MATE2-K, MRP1, and BCRP.
Co-administration with ritonavir, a dual inhibitor of OATP1B/CYP3A, or with itraconazole, a strong CYP3A inhibitor, resulted in no clinically meaningful increase in exposures of Enhertu or the released topoisomerase I inhibitor, DXd. No dose adjustment is required during co-administration of Enhertu with medicinal products that are inhibitors of OATP1B or CYP3A.
No clinically meaningful interaction is expected with medicinal products that are inhibitors of P-glycoprotein (P-gp), MATE2-K, MRP1, or BCRP transporters.

Effects of Enhertu on the pharmacokinetics of other medicinal products

In vitro studies indicate DXd does not inhibit or induce major CYP450 enzymes including CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A. *In vitro* studies indicate that DXd does not inhibit OAT1, OAT3,

OCT1, OCT2, OATP1B3, MATE1, MATE2-K, P-gp, BCRP, or BSEP transporters. No clinically meaningful drug-drug interaction is expected with medicinal products that are substrates of OAT1 or OATP1B1 transporters.

Pregnancy, lactation

Women of childbearing potential/contraception in males and females

Pregnancy status of women of childbearing potential should be verified prior to initiation of Enhertu. Women of childbearing potential should use effective contraception during treatment with Enhertu and for at least 7 months following the last dose.
Men with female partners of childbearing potential should use effective contraception during treatment with Enhertu and for at least 4 months following the last dose.

Pregnancy

There are no available data on the use of Enhertu in pregnant women. However, in postmarketing reports, use of trastuzumab, a HER2 receptor antagonist, during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Based on findings in animals and its mechanism of action, the topoisomerase I inhibitor component of Enhertu, DXd, can also cause embryo-foetal harm when administered to a pregnant woman (see section “Preclinical data”).
Enhertu must not be used during pregnancy unless clearly necessary. If Enhertu is administered during pregnancy, or if a woman becomes pregnant during treatment or within 7 months following the last dose of Enhertu, it is necessary to point out the possibility of harm to the foetus.

Lactation

It is not known if trastuzumab deruxtecan is excreted in human milk. Due to the potential for serious adverse reactions in breast-feeding infants, women should discontinue breast-feeding prior to initiating treatment with Enhertu and breast-feeding must not take place during treatment. Women may begin breast-feeding 7 months after concluding treatment.

Fertility

No dedicated fertility studies have been conducted with Enhertu. Based on results from animal toxicity studies, Enhertu may impair male reproductive function and fertility (see section “Preclinical data”).
It is not known whether trastuzumab deruxtecan or its metabolites are found in seminal fluid. Before starting treatment, male patients should be advised to seek counselling on sperm storage. Male patients must not freeze or donate sperm throughout the treatment period, and for at least 4 months after the final dose of Enhertu.

Effects on ability to drive and use machines

Enhertu is not expected to affect patients' ability to drive or use machines. Because of potential adverse reactions such as fatigue, headache and dizziness (see section "Undesirable effects"), patients should be advised to use caution when driving or operating machinery.

Undesirable effects

Summary of the safety profile

The pooled safety population has been evaluated for patients who received at least one dose of Enhertu 5.4 mg/kg and above (n = 2145) across multiple tumour types in clinical studies. The median duration of treatment in this pool was 8.05 months (range: 0.2 to .45.1 months).

- The most common adverse reactions were nausea (73.7%), fatigue (57.0%), vomiting (40.9%), decreased appetite (38.7%), neutropenia (37.6%), anaemia (37.4%), alopecia (36.9%), constipation (33.9%), diarrhoea (30.6%), thrombocytopenia (26.3%), leukopenia (25.6%), transaminases increased (25.6%), and musculoskeletal pain (23.6%), .
- The most common serious adverse reactions were ILD/pneumonitis (4.2%), pneumonia (2.2%), vomiting (1.5%), decreased appetite (1.4%), nausea (1.3%), and anaemia (1.2%).
- The most common National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v.5.0) Grade 3 or 4 adverse reactions were neutropenia (20.4%), anaemia (13.6%), leukopenia (8.6%), fatigue (8.4%), thrombocytopenia (6.4%), nausea (5.8%), lymphopenia (5.6%), transaminases increased (3.9%), hypokalaemia (3.8%), decreased appetite (3.5%), vomiting (2.5%), diarrhoea (2.1%), pneumonia (1.9%), febrile neutropenia (1.5 %), ILD/pneumonitis (1.1%), dyspnoea (1.1%), weight decreased (1.1%), and ejection fraction decreased (1.1%).

  Grade 5 adverse reactions occurred in 1.8% of patients, including ILD (1.4%).
- Dose interruptions due to adverse reactions occurred in 35.5% of patients treated with Enhertu. The most frequent adverse reactions associated with dose interruption were neutropenia (14.1%), anaemia (5.6%), fatigue (5.1%), leukopenia (3.9%), thrombocytopenia (2.9%); upper respiratory tract infection (2.9%), ILD (2.9%), and pneumonia (2.3%). Dose reductions occurred in 24.1% of patients treated with Enhertu. The most frequent adverse reactions associated with dose reduction were fatigue (6.7%), nausea (5.4%), neutropenia (4.2%), decreased appetite (2.4%), and thrombocytopenia (2.4%). Discontinuation of therapy due to an adverse reaction occurred in 14.5% of patients treated with Enhertu. The most frequent adverse reaction associated with permanent discontinuation was ILD/pneumonitis (10.3%).

Tabulated list of adverse reactions

The adverse reactions in patients who received at least one dose of Enhertu in clinical studies are presented in Table 3. The adverse reactions are listed by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

Table 3: Adverse reactions in patients treated with trastuzumab deruxtecan 5.4 mg/kg and above in multiple tumour types

System organ class/preferred term or grouped term	Any Grade (%)		Grade 3-4 (%)
Infections and infestations			
Upper respiratory tract infection[a]	Very common	17.7	0.3
Pneumonia	Common	6.7	1.9
Blood and lymphatic system disorders			
Neutropenia[b]	Very common	37.6	20.4
Anaemia[c]	Very common	37.4	13.6
Thrombocytopenia[d]	Very common	26.3	6.4
Leukopenia[e]	Very common	25.6	8.6
Lymphopenia[f]	Very common	11.3	5.6
Febrile neutropenia	Common	1.6	1.5
Metabolism and nutrition disorders			
Decreased appetite	Very common	38.7	3.5
Hypokalaemia[g]	Very common	11.8	3.8
Dehydration	Common	3.2	0.6
Nervous system disorders			
Headache[h]	Very common	15.3	0.2
Peripheral neuropathy[i]	Very common	10.2	0.2
Dizziness	Common	9.2	0.3

System organ class/preferred term or grouped term	Any Grade (%)		Grade 3-4 (%)
Dysgeusia	Common	8.3	0
Eye disorders			
Dry eye	Common	5.1	0.1
Vision blurred[j]	Common	3.6	0
Cardiac disorders			
Ejection fraction decreased[k]	Very common	14.8	1.1
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease[l]	Very common	13.8	1.1
Cough	Very common	13.8	0.1
Dyspnoea	Very common	10.4	1.1
Epistaxis	Common	9.4	0.1
Gastrointestinal disorders			
Nausea	Very common	73.7	5.8
Vomiting	Very common	40.9	2.5
Constipation	Very common	33.9	0.3
Diarrhoea	Very common	30.6	2.1
Abdominal pain[m]	Very common	17.6	0.9
Stomatitis[n]	Very common	14.4	0.7
Dyspepsia	Common	9.2	0
Abdominal distension	Common	3.6	0.1
Gastritis	Common	1.8	0.1
Flatulence	Common	1.8	0
Hepatobiliary disorders			
Transaminases increased[o]	Very common	25.6	3.9
Blood alkaline phosphatase increased	Common	8.9	0.8
Blood bilirubin increased[p]	Common	7.4	0.9

System organ class/preferred term or grouped term	Any Grade (%)		Grade 3-4 (%)
Skin and subcutaneous tissue disorders			
Alopecia	Very common	36.9	0.2
Rash[q]	Common	8.9	0.1
Pruritus	Common	5.4	0.1
Skin hyperpigmentation[r]	Common	4.2	0
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain[s]	Very Common	23.6	0.8
Renal and urinary disorders			
Blood creatinine increased	Common	3.8	0.1
General disorders and administration site conditions			
Fatigue[t]	Very common	57.0	8.4
Weight decreased	Very common	17.0	1.1
Pyrexia	Very common	14.9	0.4
Oedema peripheral	Common	8.7	0.1
Injury, poisoning and procedural complications			
Infusion-related reactions[u]	Common	1.2	0

[a] Includes influenza, influenza like illness, nasopharyngitis, pharyngitis, sinusitis, rhinitis, laryngitis, and upper respiratory tract infection.

[b] Includes neutropenia and neutrophil count decreased.

[c] Includes anaemia, haemoglobin decreased, red blood cell count decreased, and haematocrit decreased.

[d] Includes thrombocytopenia and platelet count decreased.

[e] Includes leukopenia and white blood cell count decreased.

[f] Includes lymphopenia and lymphocyte count decreased.

[g] Includes hypokalaemia and blood potassium decreased.

[h] Includes headache, sinus headache, and migraine.

[i] Includes peripheral neuropathy, peripheral sensory neuropathy, and paraesthesia.

[j] Vision blurred (grouped term) includes PTs of vision blurred and visual impairment.

[k] Includes laboratory parameters of LVEF decrease (n=309) and/or preferred terms of ejection fraction decreased (n=63), cardiac failure (n=3) cardiac failure congestive (n=1), and left ventricular dysfunction (n=3).

[l] Interstitial lung disease includes events that were adjudicated as ILD: pneumonitis (n=158), interstitial lung disease (n=111), organising pneumonia (n=10), pneumonia (n=5), pneumonia fungal (n=1), pulmonary mass (n=1), acute respiratory failure (n=1), lung infiltration (n=1), lymphangitis (n=1), pulmonary fibrosis (n=1), radiation pneumonitis (n=3), respiratory failure (n=10), idiopathic interstitial pneumonia (n=1), lung disorder (n=1), pulmonary toxicity (n=2), hypersensitivity pneumonia (n=1), lung opacity (n=2), and alveolitis (n=2).

[m] Includes abdominal discomfort, gastrointestinal pain, abdominal pain, abdominal pain lower, and abdominal pain upper.

[n] Includes stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, oral mucosal blistering, and oral mucosal eruption.

[o] Includes transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, liver function test increased, hypertransaminasaemia, and hepatic function abnormal.

[p] Includes blood bilirubin increased, hyperbilirubinaemia, bilirubin conjugated increased and blood bilirubin unconjugated increased.

[q] Includes rash, rash pustular, rash maculopapular, rash papular, rash macular, and rash pruritic.

[r] Includes skin hyperpigmentation, skin discolouration and pigmentation disorder.

[s] Includes back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain and limb discomfort.

[t] Includes asthenia, fatigue, malaise, and lethargy.

[u] Cases of infusion-related reactions include infusion related reaction (n=22) and hypersensitivity (n=3).

Description of selected undesirable effects

Interstitial lung disease/pneumonitis

In clinical studies across multiple tumour types (n = 2145), ILD occurred in 13.8% of patients treated with Enhertu 5.4 mg/kg and above. Most ILD cases were Grade 1 (3.6%) and Grade 2 (7.7%). Grade 3 cases occurred in 1.0% and Grade 4 cases occurred in 0.05% of patients. Grade 5 events occurred in 1.4% of patients. Median time to first onset was 5.5 months (range: -0.5 to 31.5).

In clinical studies with patients treated with Enhertu 5.4 mg/kg and above across multiple tumour types, the incidence of ILD with moderate renal impairment (21.2%) was higher compared to patients with normal renal function (11.8%).

Neutropenia

In clinical studies (n = 2145) across multiple tumour types in patients treated with Enhertu 5.4 mg/kg and above, neutropenia was reported in 37.6% of patients and 20.4% had Grade 3 or 4 events. Median time to first onset was 22 days (range: 1 day to 31.9 months), and median duration of the first event was 20 days (range: 1 day to 17.2 months). Febrile neutropenia was reported in 1.6% of patients and 0.1% were Grade 5 (see section “Warnings and precautions”).

Left ventricular ejection fraction decrease

In the 2145 patients, across multiple tumour types in clinical studies who received Enhertu 5.4 mg/kg and above, LVEF decrease was reported in 69 patients (3.2%), of which 11 (0.5%) were Grade 1, 48 (2.2%) were Grade 2, and 10 (0.5%) were Grade 3. The observed frequency of LVEF decreased based on laboratory parameters (echocardiogram or multigated acquisition [MUGA] scanning) was 290/1934 (15.0%) for Grade 2, and 19/1934 (1.0%) for Grade 3. Treatment with Enhertu has not been studied in patients with LVEF less than 50% prior to initiation of treatment.

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. The measurement of antibodies is dependent on assay sensitivity and specificity. The rate of antibody positivity found is dependent on numerous factors; therefore, comparison of the rates with other therapies may be misleading. Across all doses evaluated in clinical studies, 2.1% (47/2213) of evaluable patients developed antibodies against trastuzumab deruxtecan following treatment with Enhertu. The incidence of treatment-emergent neutralising antibodies against trastuzumab deruxtecan was 0.1% (2/2213). Due to the limited number of patients who tested positive for ADA, the effect of ADA on safety and efficacy of Enhertu is unknown.

Children and adolescents

Safety has not been established in this population.

Elderly patients

Of the 2145 patients across multiple tumour types in clinical studies treated with Enhertu 5.4 mg/kg and above, 29.0% were 65 years or older and 5.3% were 75 years or older. The incidence of Grade 3-4 adverse reactions observed in patients 65 years or older (53.6%) and in younger patients (48.0%) was similar.

Reporting suspected adverse reactions after authorisation of the medicinal product is very important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions online via the ElViS portal (Electronic Vigilance System). You can obtain information about this at www.swissmedic.ch.

Overdose

There is no information on overdose with trastuzumab deruxtecan. In the event of overdose, patients should be monitored and appropriate supportive care should be given.

Properties/Effects

ATC code

L01FD04

Mechanism of action

Enhertu, trastuzumab deruxtecan, is a HER2-targeted antibody-drug conjugate (ADC). The antibody is a humanised anti-HER2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd), bound by a tetrapeptide-based cleavable linker. The ADC is stable in plasma. Following binding to HER2 on tumour cells, trastuzumab deruxtecan undergoes internalisation and intracellular linker cleavage by lysosomal enzymes that are upregulated in cancer cells. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. DXd, an exatecan derivative, is approximately 10 times more potent than SN-38, the active metabolite of irinotecan.

Pharmacodynamics

The administration of multiple doses of trastuzumab deruxtecan (6.4 mg/kg every 3 weeks) did not show any clinically meaningful effect on the QTc interval (i.e., >20 ms) in an open-label, single-arm study in 51 patients with HER2-expressing metastatic breast cancer.
In the DESTINY-Breast04 study, it was observed that 21.6% of patients had a QTcF prolongation > 30 ms from baseline, 5.7% of patients had a QTcF prolongation > 60 ms from baseline and 1.9% of patients had a QTcF measurement of > 500 ms.

Clinical efficacy

DESTINY-Breast03
The efficacy and safety of Enhertu were studied in DESTINY-Breast03, a multicentre, open-label, active controlled, randomised, two-arm phase 3 study that enrolled patients with HER2-positive, unresectable or metastatic breast cancer who received prior trastuzumab and taxane therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy.
Archival breast tumour samples were required to show HER2 positivity defined as HER2 IHC 3+ or ISH-positive. The study excluded patients with a history of (non-infectious) ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis at screening, patients with untreated and symptomatic brain metastases, patients with a history of clinically significant cardiac disease, patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 and patients with prior treatment with an anti-HER2 antibody-drug conjugate in the metastatic setting. Patients were randomized 1:1 to receive either Enhertu 5.4 mg/kg (n=261) or trastuzumab emtansine 3.6 mg/kg (n=263) administered by intravenous infusion once every three weeks. Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease.

Treatment was administered until disease progression, death, withdrawal of consent, or unacceptable toxicity.

The primary efficacy outcome measure was progression-free survival (PFS) as evaluated by blinded independent central review (BICR) according to RECIST v1.1. Overall survival (OS) was a key secondary efficacy outcome measure.

Patient demographics were balanced between treatment arms. Of the 524 patients randomised, the baseline demographic and disease characteristics were: median age 54 years (range: 20 to 83); 65 years or older (20.2%); 75 years or older (3.1%), female (99.6%); Asian (59.9%), White (27.3%), Black or African-American (3.6%); ECOG performance status 0 (62.8%) or 1 (36.8%); hormone receptor status (positive: 51.9%); presence of visceral disease (73.3%); presence of brain metastases at baseline (15.6%); and (48.3%) patients received one line of prior systemic therapy in the metastatic setting. The percentage of patients who were previously treated with pertuzumab was 61.1%. The percentage of patients who had not received prior treatment for metastatic disease was 9.5% and 6.7% of patients had received exactly one prior anti-HER2 therapy that was intended for the neoadjuvant or adjuvant therapy and experienced disease progression during or within 6 months of completing treatment (12 months for pertuzumab).

At the prespecified interim analysis for PFS (data cutoff 21 May 2021) based on 245 events (73% of total events planned for final analysis), the study demonstrated a statistically significant improvement in PFS per BICR in patients randomized to Enhertu compared to trastuzumab emtansine. At the prespecified OS analysis based on 169 events (data cutoff 25 July 2022), the study also demonstrated statistically significant improvement in OS. An updated PFS per BICR was provided at the time of this OS analysis.[1]

Table 4: Efficacy results in DESTINY Breast03[1]

Efficacy Parameter	**Enhertu N=261**	**trastuzumab emtansine N=263**
Progression-Free Survival (PFS) Primary end-point (BICR)[a]		
Number of events (%)	87 (33.3)	158 (60.1)
Median, months (95% CI)	NR (18.5, NE)	6.8 (5.6, 8.2)
Hazard ratio (95% CI)	0.28 (0.22, 0.37)	
p-value	p< 0.0001	
Overall Survival (OS)[b]		
Number of events (%)	72 (27.6)	97 (36.9)
Median, months (95% CI)	NR (40.5, NE)	NR (34.0, NE)
Hazard ratio (95% CI)	0.64 (0.47, 0.87)	
p-value[c]	p=0.0037	
Survival at 12 months (95% CI)	94.1% (90.4, 96.4)	86.0% (81.1, 89.8)

Survival at 24 months (95% CI)	77.4 (71.7, 82.1)	69.9 (63.7, 75.2)
PFS (BICR) (updated)[b]		
Number of events (%)	117 (44.8)	171 (65.0)
Median, months (95% CI)	28.8 (22.4, 37.9)	6.8 (5.6, 8.2)
Hazard ratio (95% CI)	0.33 (0.26, 0.43)	

CI = confidence interval; NE=not estimable; NR = not reached

[a] Data cutoff 21 May 2021
[b] Data cutoff 25 July 2022 for a pre-planned OS interim analysis
[c] The p-value is based on a stratified log-rank test; crossed the efficacy boundary of 0.013.

DESTINY-Breast02

The efficacy and safety of Enhertu were evaluated in study DESTINY-Breast02, a Phase 3, randomised, multicenter, open-label, active-controlled study that enrolled patients with unresectable or metastatic HER2-positive breast cancer.

The study included adult patients with unresectable or metastatic HER2-positive breast cancer who were resistant or refractory to prior trastuzumab emtansine. Archival breast tumor samples were required to show HER2 positivity defined as HER2 IHC 3+ or ISH-positive. The study excluded patients with a history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis at screening, patients with untreated and symptomatic brain metastases and patients with a history of clinically significant cardiac disease. Patients were randomized 2:1 to receive either Enhertu 5.4 mg/kg (N=406) by intravenous infusion every three weeks or treatment of physician's choice (N=202, trastuzumab plus capecitabine or lapatinib plus capecitabine). Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease. Treatment was administered until disease progression, death, withdrawal of consent, or unacceptable toxicity.

The primary efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) based on RECIST v1.1. Overall survival (OS) was a key secondary efficacy outcome measure.

Demographic and baseline disease characteristics were similar between treatment arms. Of the 608 patients randomized, the median age was 54 years (range 22 to 88); female (99.2%); White (63.2%), Asian (29.3%), Black or African American (2.8%); ECOG performance status 0 (57.4%) or 1 (42.4%); hormone receptor status (positive: 58.6%); presence of visceral disease (78.3%); presence of brain metastases at baseline (18.1%), and 4.9% of patients received one line of prior systemic therapy in the metastatic setting.

The study demonstrated a statistically significant improvement in PFS per BICR and OS in patients randomized to Enhertu compared to treatment of physician's choice.
Efficacy results are summarized in Table 5.

Table 5: Efficacy Results in DESTINY-Breast02

Efficacy Parameter	Enhertu N=406	Treatment of Physician's Choice N=202
PFS per BICR		
Number of events (%)	200 (49.3)	125 (61.9)
Median, months (95% CI)	17.8 (14.3, 20.8)	6.9 (5.5, 8.4)
Hazard ratio (95% CI)	0.36 (0.28, 0.45)	
p-value	p<0.000001†	
Overall Survival (OS)		
Number of events (%)	143 (35.2)	86 (42.6)
Median, months (95% CI)	39.2 (32.7, NE)	26.5 (21.0, NE)
Hazard ratio (95% CI)	0.66 (0.50, 0.86)	
p-value[a]	p=0.0021	
Survival at 12 months (95% CI)	89.4% (85.9, 92.1)	74.7% (67.6, 80.4)
Survival at 24 months (95% CI)	65.9% (60.7, 70.7)	54.3% (46.3, 61.6)

CI = confidence interval; NE=not estimable
†presented as 6 decimal places
[a] The p-value is based on a stratified log-rank test; crossed the efficacy boundary of 0.004

DESTINY-Breast01

The efficacy and safety of Enhertu were demonstrated in DESTINY-Breast01, a multicentre, open-label, single-arm Phase 2 study that enrolled patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2-based regimens, including trastuzumab emtansine (100%), trastuzumab (100%), and pertuzumab (65.8%). Archival breast tumour samples were required to show HER2-positivity defined as HER2 IHC 3+ or ISH-positive. The study excluded patients with a history of treated ILD or ILD at screening, patients with a history of clinically significant cardiac disease as well as patients with clinically unstable brain metastases. Enhertu was administered by intravenous infusion at 5.4 mg/kg once every three weeks until disease progression or unacceptable toxicity. The primary efficacy outcome measure was confirmed objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in the

intent-to-treat (ITT) population as evaluated by independent central review. Secondary efficacy outcome measures were duration of response (DOR) and progression-free survival (PFS).
Of the 184 patients enrolled in DESTINY-Breast01, baseline demographic and disease characteristics were: median age 55 years (range 28 to 96); female (100%); White (54.9%), Asian (38.0%), Black or African-American (2.2%); Eastern Cooperative Oncology Group (ECOG) performance status 0 (55.4%) or 1 (44.0%); hormone receptor status (positive: 52.7%); presence of visceral disease (91.8%); median number of prior therapies in the metastatic setting: 5 (range: 2 to 17); prior pertuzumab therapy (65.8%); sum of diameters of target lesions (<5 cm: 42.4%, ≥5 cm: 50.0%).
Efficacy results are summarised in Table 6.

Table 6: Efficacy results in DESTINY-Breast01 (intent-to-treat analysis set)

	DESTINY-Breast01 **N = 184**
Confirmed objective response rate (95% CI)	61.4% (54.0, 68.5)
Complete response (CR)	6.5%
Partial response (PR)	54.9%
Duration of response[‡]	
Median, months (95% CI)	20.8 (15.0, NR)
% with duration of response ≥6 months (95% CI)[§]	81.5% (72.2, 88.0)

ORR 95% CI calculated using Clopper-Pearson method
CI = confidence interval
95% CIs calculated using Brookmeyer-Crowley method
[‡]Includes 73 patients with censored data
[§]Based on Kaplan-Meier estimation
NR = not reached

Consistent anti-tumour activity was observed across pre-specified subgroups based on prior pertuzumab therapy and hormone receptor status.

DESTINY-Breast04
The efficacy of Enhertu was studied in DESTINY-Breast04, a phase 3, randomised, multicentre, open-label study that enrolled 557 adult patients with unresectable or metastatic HER2-low breast cancer. The study included 2 cohorts: 494 hormone receptor positive (HR+) patients and 63 hormone receptor negative (HR-) patients. HER2-low expression was defined as IHC 1+ or IHC 2+/ISH-, as determined by the PATHWAY/VENTANA anti-HER-2/neu (4B5) and when applicable, the INFORM HER2 Dual ISH assay, evaluated at a central laboratory. Patients must have received chemotherapy in the metastatic setting or have developed disease recurrence during or within 6 months of

completing adjuvant chemotherapy. Patients who were HR+ must have received at least one endocrine therapy or be ineligible for endocrine therapy. Patients were randomised 2:1 to receive either Enhertu 5.4 mg/kg (N = 373) by intravenous infusion every three weeks or physician's choice of chemotherapy (N = 184, eribulin 51.1%, capecitabine 20.1%, gemcitabine 10.3%, nab paclitaxel 10.3%, or paclitaxel 8.2%). Randomisation was stratified by HER2 IHC status of tumour samples (IHC 1+ or IHC 2+/ISH-), number of prior lines of chemotherapy in the metastatic setting (1 or 2), and HR status/prior CDK4/6i treatment (HR+ with prior CDK4/6 inhibitor treatment, HR+ without prior CDK4/6 inhibitor treatment, or HR-). Treatment was administered until disease progression, death, withdrawal of consent, or unacceptable toxicity. The study included patients with LVEF ≥50%. The study excluded patients with a history of ILD/pneumonitis requiring treatment with steroids or current or suspected ILD/pneumonitis at screening and patients with clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses. Patients were also excluded for clinically significant cardiac disease including corrected QT interval (QTc) prolongation >470 ms for female patients or >450 ms in male patients, untreated or symptomatic brain metastases or ECOG performance status > 1.

The primary efficacy outcome measure was progression-free survival (PFS) in patients with HR+ breast cancer assessed by BICR based on RECIST v1.1. Key secondary efficacy outcome measures were PFS assessed by BICR based on RECIST v1.1 in the overall population (all randomised HR+ and HR- patients), overall survival (OS) in HR+ patients, and OS in the overall population.

Demographics and baseline tumour characteristics were similar between treatment arms. Of the 557 patients randomised, the median age was 57 years (range: 28 to 81); 23.5% were age 65 or older; 4.1% were age 75 or older; 99.6% were female and 0.4% were male; 47.9% were White, 40.0% were Asian, and 1.8% were Black or African American. Patients had an ECOG performance status of 0 (54.8%) or 1 (45.2%) at baseline; 57.6% were IHC 1+, 42.4% were IHC 2+/ISH-; 69.8% had liver metastases, 32.9% had lung metastases, and 5.7% had brain metastases. In the metastatic setting, patients had a median of 3 prior lines of systemic therapy (range: 1 to 9) with 57.6% having 1 and 40.9% having 2 prior chemotherapy regimens; 3.9% were early progressors (progression in the neo/adjuvant setting). In HR+ patients, the median number of prior lines of endocrine therapy was 2 (range: 0 to 9) and 70% had prior CDK4/6 inhibitor treatment.

The study demonstrated a statistically significant and clinically meaningful improvement in OS and PFS in patients randomised to Enhertu compared to chemotherapy in both the HR+ cohort and the overall population. Efficacy results are summarized in Table 7.

Table 7: Efficacy results in DESTINY-Breast04

Efficacy parameter	HR+ cohort	
	Enhertu (N = 331)	Chemotherapy (N = 163)
Overall survival		
Number of events (%)	126 (38.1)	73 (44.8)
Median, months (95% CI)	23.9 (20.8, 24.8)	17.5 (15.2, 22.4)
Hazard ratio (95% CI)	0.64 (0.48, 0.86)	
p-value	0.0028	
Progression-free survival per BICR		
Number of events (%)	211 (63.7)	110 (67.5)
Median, months (95% CI)	10.1 (9.5, 11.5)	5.4 (4.4, 7.1)
Hazard ratio (95% CI)	0.51 (0.40, 0.64)	
p-value	< 0.0001	

CI = confidence interval

The results in the HR-negative cohort are consistent with the results in the HR+ cohort. In the full analysis set (FAS), median OS was 23.4 months (95% CI: 20.0, 24.8) in patients randomised to Enhertu compared to 16.8 months (95% CI: 14.5, 20.0) in patients randomised to chemotherapy with a hazard ratio of 0.64 (95% CI: 0.49, 0.84). Median PFS was 9.9 months (95% CI: 9.0, 11.3) in patients randomised to Enhertu and 5.1 months (95% CI: 4.2, 6.8) in patients randomised to chemotherapy with a hazard ratio of 0.50 (95% CI: 0.40, 0.63).

DESTINY-Gastric02

The efficacy and safety of Enhertu were studied in DESTINY-Gastric02, a Phase 2, multicenter, open-label, single-arm study conducted at sites in Europe and the United States. The study enrolled patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed on a prior trastuzumab-containing regimen, including subjects who progressed on or within 6 months of completing a trastuzumab-containing adjuvant therapy. Patients were required to have centrally confirmed HER2 positivity defined as IHC 3+ or IHC 2+/ISH-positive based on a tumor biopsy obtained after progression on or after a first-line trastuzumab-containing regimen. The study included patients with LVEF ≥50%. The study excluded patients with a history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis at screening, patients with a history of clinically significant cardiac disease [including patients with QT interval corrected for heart rate (QTc) prolongation to >470 milliseconds (ms) for females or >450 ms for males and patients with a history of symptomatic congestive heart failure (New York Heart Association Class II to IV)], and patients with active brain metastases. Enhertu was administered by intravenous infusion at 6.4 mg/kg every three weeks until disease progression, death, withdrawal of consent, or unacceptable toxicity. The primary efficacy outcome measure was confirmed ORR assessed by ICR based on RECIST v1.1. DOR, PFS, and OS were secondary endpoints.

Of the 79 patients enrolled in DESTINY-Gastric02, demographic and baseline disease characteristics were: median age 61 years (range 20 to 78); 72% were male; 87% were White, 5.0% were Asian, and 1.0% were Black or African American. Patients had an ECOG performance status of either 0 (37%) or 1 (63%); 34% had gastric adenocarcinoma and 66% had GEJ adenocarcinoma; 86% were IHC 3+ and 13% were IHC 2+/ISH-positive, and 63% had liver metastases.

Efficacy results for ORR, DOR, PFS, and OS are summarized in Table 8.

Table 8: Efficacy Results in DESTINY-Gastric02 (Full Analysis Set[*])

Efficacy Parameter	**DESTINY-Gastric02** **N=79**
Data cut-off date 8 November 2021	
Confirmed Objective Response Rate (ORR)[†] % (95% CI)[‡]	 41.8 (30.8, 53.4)
Complete response n (%)	4 (5.1)
Partial response n (%)	29 (36.7)
Duration of Response (DOR) Median[§], months (95% CI)[¶]	 8.1 (5.9, NE)

*Includes all patients who received at least one dose of Enhertu

[†]Assessed by independent central review

[‡]Calculated using Clopper-Pearson method

[§]Based on Kaplan-Meier estimate

[¶]Calculated using the Brookmeyer and Crowley method

Additional efficacy results (data cut-off date 8 November 2021) for Enhertu (n=79) were median progression-free survival (PFS) of 5.6 months (95% CI: 4.2, 8.3) and median overall survival (OS) of 12.1 months (95% CI: 9.4, 15.4).

DESTINY-Gastric01

The efficacy and safety of Enhertu were studied in DESTINY-Gastric01, a Phase 2, multicenter, open-label, randomised study conducted at sites in Japan and South Korea. The study included adult patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine agent, and a platinum agent. Patients were randomised 2:1 to receive either Enhertu (N=126) or physician's choice of chemotherapy: either irinotecan (N=55) or paclitaxel (N=7). Randomization was stratified by HER2 status (IHC 3+ or IHC 2+/ISH-positive), ECOG performance status (0 or 1), and region (Japan or South Korea). Enhertu was administered by intravenous infusion at 6.4 mg/kg every three weeks. Irinotecan monotherapy was administered by intravenous infusion biweekly at 150 mg/m^2. Paclitaxel

monotherapy was administered by intravenous infusion weekly at 80 mg/m^2. Tumour samples were required to have centrally confirmed HER2 positivity defined as IHC 3+ or IHC 2+/ISH-positive. The study excluded patients with a history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis at screening, patients with a history of clinically significant cardiac disease, and patients with active brain metastases. Treatment was administered until disease progression, death, withdrawal of consent, or unacceptable toxicity. The primary efficacy outcome measure was unconfirmed ORR assessed by ICR based on RECIST v1.1. OS, PFS, DOR, and confirmed ORR were secondary outcome measures.

Demographic and baseline disease characteristics were similar between treatment arms. Of the 188 patients, the median age was 66 years (range 28 to 82); 76% were male; 100% were Asian. Patients had an ECOG performance status of either 0 (49%) or 1 (51%); 87% had gastric adenocarcinoma and 13% had GEJ adenocarcinoma; 76% were IHC 3+ and 23% were IHC 2+/ISH-positive; 65% had inoperable advanced cancer; 35% had postoperative recurrent cancer; 54% had liver metastases; 29% had lung metastases; 55% had two and 45% had three or more prior regimens in the locally advanced or metastatic setting.

At the time of the primary analysis (data cut-off: 8 November 2019), the study demonstrated a statistically significant and clinically meaningful improvement in ORR and OS in the Enhertu-treated group compared to the chemotherapy-treated group. Efficacy results (data cut-off: 3 June 2020) are summarized in Table 9.

Table 9: Efficacy Results in DESTINY-Gastric01 (Intent-to-Treat Analysis Set)

Efficacy Parameter	**Enhertu N=126**	**Physician's Choice of Chemotherapy N=62**
Confirmed Objective Response Rate (ORR)[§]		
n (%)	50 (39.7)	7 (11.3)
95% CI[¶]	(31.1, 48.8)	(4.7, 21.9)
p-value[‡,#,**]	p<0.0001	
Complete Response n (%)	10 (7.9)	0 (0.0)
Partial Response n (%)	40 (31.7)	7 (11.3)
Stable Disease n (%)	57 (45.2)	31 (50.0)
Progressive Disease n (%)	15 (11.9)	18 (29.0)
Not Evaluable n (%)	4 (3.2)	6 (9.7)
Overall Survival (OS)[*]		
Median, months (95% CI)[†]	12.5 (10.3, 15.2)	8.9 (6.4,10.4)
Hazard ratio (95% CI)[‡]	0.60 (0.42, 0.86)	
Stratified Log-rank p-value[‡,**]	p=0.0051	

Efficacy Parameter	Enhertu N=126	Physician's Choice of Chemotherapy N=62
Progression-free Survival (PFS)[§]		
Median, months (95% CI)[†]	5.6 (4.3, 6.9)	3.5 (2.0, 4.3)
Hazard ratio (95% CI)[‡]	0.47 (0.31, 0.71)	
Duration of Confirmed Response (DOR)[§]		
Median, months (95% CI)[†]	12.5 (5.6, NE)	3.9 (3.0, 4.9)

CI = confidence interval; NE = not estimable
[§]Assessed by independent central review
[¶]95% exact binomial confidence interval
[‡]Stratified by region
[#]Based on the Cochran-Mantel-Haenszel test
[**]Nominal p-value provided for descriptive purposes. Statistical significance was established at the primary analysis for OS (p=0.0097) and unconfirmed ORR (p<0.0001)
[*]OS was evaluated following a statistically significant outcome of ORR.
[†]Median based on Kaplan-Meier estimate; 95% CI for median calculated using Brookmeyer-Crowley method

Pharmacokinetics

At the recommended dosage of trastuzumab deruxtecan for patients with metastatic breast cancer, the geometric mean (coefficient of variation [CV]%) C_{max} of trastuzumab deruxtecan and DXd were 133 µg/mL (19%) and 4.7 ng/mL (43%), respectively, and the AUC of trastuzumab deruxtecan and DXd were 780 µg·day/mL (27%) and 29 ng·day/mL (42%), respectively, based on population pharmacokinetic analysis.
Moderate accumulation (approximately 35% in cycle 3 compared to cycle 1) of trastuzumab deruxtecan was observed.

Absorption

Trastuzumab deruxtecan is administered intravenously. There have been no studies performed with other routes of administration.

Distribution

Based on population pharmacokinetic analysis, the volume of distribution of the central compartment (V_c) of trastuzumab deruxtecan and topoisomerase I inhibitor, DXd, was estimated to be 2.68 L and 28.0 L, respectively.
In vitro, the mean human plasma protein binding of the topoisomerase I inhibitor, DXd, was approximately 97%.
In vitro, the blood to plasma concentration ratio of DXd was approximately 0.6.

Metabolism

Trastuzumab deruxtecan undergoes intracellular cleavage by lysosomal enzymes to release the DXd. The humanised HER2 IgG1 monoclonal antibody is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
In vitro metabolism studies in human liver microsomes indicate that DXd is metabolised mainly by CYP3A4 via oxidative pathways.

Elimination

Following intravenous administration of trastuzumab deruxtecan in patients with metastatic HER2-positive, HER2-low breast cancer or HER2-mutant NSCLC, the clearance of trastuzumab deruxtecan in population pharmacokinetic analysis was calculated to be 0.4 L/day and the clearance of DXd was 18.4 L/h. In patients with locally advanced or metastatic gastric or GEJ adenocarcinoma, trastuzumab deruxtecan clearance was 20% higher than in patients with metastatic HER2-positive breast cancer. In cycle 3, the apparent elimination half-life ($t_{1/2}$) of trastuzumab deruxtecan and released DXd was approximately 7 days. Moderate accumulation (approximately 35% in cycle 3 compared to cycle 1) of trastuzumab deruxtecan was observed.
Following intravenous administration of DXd to rats, the major excretion pathway was faeces via the biliary route. DXd was the most abundant component in urine, faeces, and bile. Following single intravenous administration of trastuzumab deruxtecan (6.4 mg/kg) to monkeys, unchanged released DXd was the most abundant component in urine and faeces. DXd excretion was not studied in humans.

Linearity/non-linearity

The exposure of trastuzumab deruxtecan and released DXd when administered intravenously increased in proportion to dose in the 3.2 mg/kg to 8.0 mg/kg dose range (approximately 0.6 to 1.5 times the recommended dose) with low to moderate interindividual variability.

Special populations

Based on population pharmacokinetic analysis, race, ethnicity, sex and body weight (27.3-125.4 kg) did not have a clinically meaningful effect on exposure of trastuzumab deruxtecan or released DXd.

Elderly patients

The population pharmacokinetic analysis showed that age (range 20-96 years) did not affect the pharmacokinetics of trastuzumab deruxtecan.

Patients with renal impairment

No dedicated renal impairment study was conducted. Based on population pharmacokinetic analysis including patients with mild (creatinine clearance [CLcr] ≥60 and <90 mL/min) or moderate (CLcr ≥30 and <60 mL/min) renal impairment (estimated by Cockcroft-Gault), the pharmacokinetics of the

released DXd was not affected by mild or moderate renal impairment as compared to normal renal function (CLcr ≥90 mL/min).

Patients with hepatic impairment

No dedicated hepatic impairment study was conducted. Based on population pharmacokinetic analysis, the impact of changes on pharmacokinetics of trastuzumab deruxtecan in patients with mild (total bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) or moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment is not clinically meaningful.

Children and adolescents

No studies have been conducted to investigate the pharmacokinetics of trastuzumab deruxtecan in children or adolescents.

Preclinical data

Safety Pharmacology

In telemetered male cynomolgus monkeys treated with a single intravenous dose of trastuzumab deruxtecan, no effects on the cardiovascular, respiratory, or central nervous systems were observed at dose levels up to 78.8 mg/kg.

Repeated Dose Toxicity

In a six-week repeat-dose toxicity study, up to 197 mg/kg of trastuzumab deruxtecan was administered to rats once every three weeks. Toxicities were observed in intestines, lymphatic/haematopoietic organs (thymus, lymph nodes, bone marrow), kidneys, skin, testes, and incisor teeth. All changes observed, except for kidney, testicular and incisor teeth changes, were reversible following a nine-week recovery period. The severely toxic dose in 10% of the rats (STD_{10}) was determined to be >197 mg/kg (approximately 31 times the clinical dose of 5.4 mg/kg based on AUC).

In a three-month repeat-dose toxicity study, trastuzumab deruxtecan was administered to monkeys once every three weeks at 3, 10, and 30 mg/kg. Toxicities were observed in intestines, testes, skin, bone marrow, kidneys, and lungs. Pulmonary toxicity was observed at the highest dose (30 mg/kg) and was histopathologically characterised by aggregation of foamy alveolar macrophages and focal alveolus and/or interstitial inflammation, which showed reversibility after a three-month recovery period. The highest non-severely toxic dose was determined to be 30 mg/kg (approximately 7 times the clinical dose of 5.4 mg/kg based on AUC).Changes observed in other organs, except for those in the skin and kidney, also showed reversibility or a trend toward reversibility by the end of a three-month recovery period.

Genotoxicity

The topoisomerase I inhibitor component of trastuzumab deruxtecan, DXd, was clastogenic in both an *in vivo* rat bone marrow micronucleus assay and an *in vitro* Chinese hamster lung chromosome aberration assay and was not mutagenic in an *in vitro* bacterial reverse mutation assay.

Carcinogenicity

Carcinogenicity studies have not been conducted with trastuzumab deruxtecan.

Reproductive toxicity

Dedicated fertility studies have not been conducted with trastuzumab deruxtecan. Based on results from general animal toxicity studies, trastuzumab deruxtecan may impair male reproductive function and fertility.
There were no animal reproductive or developmental toxicity studies conducted with trastuzumab deruxtecan. Based on results from general animal toxicity studies, trastuzumab deruxtecan and DXd were toxic to rapidly dividing cells (lymphatic/haematopoietic organs, intestine, or testes), and DXd was genotoxic, suggesting the potential for embryotoxicity and teratogenicity.

Other information

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Sodium chloride solution for infusion must not be used for reconstitution or dilution since it may cause particulate formation.

Shelf life

Do not use this medicine after the expiry date ("EXP") stated on the container.

Shelf life after opening

Reconstituted solution
The reconstituted preparation is not preserved. It is recommended that the reconstituted solution be used immediately. If not used immediately, the reconstituted solution may be stored in a refrigerator at 2-8ºC for up to 24 hours from the time of reconstitution, protected from light.
Diluted solution
It is recommended that the diluted solution be used immediately. If not used immediately, the diluted solution may be stored at room temperature for up to 4 hours or in a refrigerator at 2-8ºC for up to 24 hours, protected from light. These storage times start from the time of reconstitution.

Special precautions for storage

Store in the refrigerator (2-8°C) until time of reconstitution.
Do not freeze.
Keep out of the reach of children.
For storage conditions after reconstitution and dilution of the medicinal product, see section “Other information”, “Shelf life after opening”.

Instructions and special precautions for handling and disposal

In order to prevent medicinal product errors, it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Enhertu (trastuzumab deruxtecan) and not trastuzumab or trastuzumab emtansine.
Appropriate procedures for the preparation of chemotherapeutic medicinal products should be used.
Appropriate aseptic technique should be used for the following reconstitution and dilution procedures.

Reconstitution

- Reconstitute immediately before dilution.
- More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted Enhertu solution required, and the number of vial(s) of Enhertu needed (see section “Dosage/Administration”).
- Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of sterile water for injection into each vial to obtain a final concentration of 20 mg/mL.
- Swirl the vial gently until completely dissolved. Do not shake.
- If not used immediately, store the reconstituted Enhertu vials in a refrigerator at 2-8ºC for up to 24 hours from the time of reconstitution, protected from light. Do not freeze.
- The product does not contain a preservative. Discard unused Enhertu after 24 hours refrigerated.

Dilution

- Withdraw the calculated amount from the vial(s) using a sterile syringe. Inspect the reconstituted solution for particulates and discoloration. The solution should be clear and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored.
- Dilute the calculated volume of reconstituted Enhertu in an infusion bag containing 100 mL of 5% glucose solution. Do not use sodium chloride solution (see section “Other information”, “Incompatibilities”). An infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and polypropylene) is recommended.
- Gently invert the infusion bag to thoroughly mix the solution. Do not shake.
- Cover the infusion bag to protect from light.
- If not used immediately, store at room temperature for up to 4 hours including preparation and infusion or in a refrigerator at 2-8ºC for up to 24 hours, protected from light. Do not freeze.

- Discard any unused portion left in the vial.

Administration

- If the prepared infusion solution was stored refrigerated (2-8ºC), it is recommended that the solution be allowed to equilibrate to room temperature prior to administration, protected from light.
- Administer Enhertu as an intravenous infusion only with a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter. Do not administer as an intravenous push or bolus.
- Cover the infusion bag to protect from light.
- Do not mix Enhertu with other medicinal products or administer other medicinal products through the same intravenous line.

Disposal

The reconstituted product contains no preservative and is intended for single use only. Discard any unused portion left in the vial.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Authorisation number

67967 (Swissmedic)

Packs

Enhertu is provided in 10 mL Type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap.
Pack containing 1 vial with 100 mg of trastuzumab deruxtecan (A)

Marketing authorisation holder

DAIICHI SANKYO (Schweiz) AG, Zürich

Date of revision of the text

January 2024